Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Glycopeptide Antibiotic Resistance Genes in Glycopeptide-Producing Organisms

C. G. Marshall, I. A. D. Lessard, I.-S. Park, G. D. Wright
C. G. Marshall
Department of Biochemistry, McMaster University, Hamilton, Ontario, Canada L8N 3Z5, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. A. D. Lessard
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I.-S. Park
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. D. Wright
Department of Biochemistry, McMaster University, Hamilton, Ontario, Canada L8N 3Z5, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.42.9.2215
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The mechanism of high-level resistance to vancomycin in enterococci consists of the synthesis of peptidoglycan terminating ind-alanyl-d-lactate instead of the usuald-alanyl-d-alanine. This alternate cell wall biosynthesis pathway is ensured by the collective actions of three enzymes: VanH, VanA, and VanX. The origin of this resistance mechanism is unknown. We have cloned three genes encoding homologs of VanH, VanA, and VanX from two organisms which produce glycopeptide antibiotics: the A47934 producer Streptomyces toyocaensis NRRL 15009 and the vancomycin producer Amycolatopsis orientalis C329.2. The predicted amino acid sequences are highly similar to those found in VRE: 54 to 61% identity for VanH, 59 to 63% identity for VanA, and 61 to 64% identity for VanX. Furthermore, the orientations of the genes,vanH, vanA, and vanX, are identical to the orientations found in vancomycin-resistant enterococci. Southern analysis of total DNA from other glycopeptide-producing organisms,A. orientalis 18098 (chloro-eremomycin producer), A. orientalis subsp. lurida (ristocetin producer), andAmycolatopsis coloradensis subsp. labeda(teicoplanin and avoparcin producer), with a probe derived from thevanH, vanA, and vanX cluster fromA. orientalis C329.2 revealed cross-hybridizing DNA in all strains. In addition, the vanH, vanA,vanX cluster was amplified from all glycopeptide-producing organisms by PCR with degenerate primers complementary to conserved regions in VanH and VanX. Thus, this gene sequence is common to all glycopeptide producers tested. These results suggest that glycopeptide-producing organisms may have been the source of resistance genes in vancomycin-resistant enterococci.

The glycopeptide antibiotic vancomycin and the structurally related antibiotic teicoplanin are considered to be the last lines of defense against a variety of serious infections caused by gram-positive organisms, such as enterococci, methicillin-resistant Staphylococcus aureus, andClostridium difficile (11). The recent rapid emergence and spread of vancomycin-resistant enterococci (VRE) has therefore become a grave concern of both medical practitioners and their patients (22, 27).

The molecular target of glycopeptide antibiotics is thed-alanyl-d-alanine (d-Ala-d-Ala) terminus of growing peptidoglycan, the rigid polymer which protects bacterial cells from osmotic lysis. By binding to this terminal dipeptide, glycopeptide antibiotics interfere with proper cell wall formation, which results in eventual cell death (6). Glycopeptide-resistant organisms avoid such a fate by modifying the drug’s peptide target, specifically, by modifying it to the depsipeptided-alanyl-d-lactate (d-Ala-d-Lac) (40). The biosynthetic machinery required to effect this transformation in vancomycin-resistant Enterococcus faecium is found on a transposable element, Tn1546, which incorporates five genes necessary and sufficient to confer high-level inducible glycopeptide resistance (2). Two of these gene products, VanR and VanS, are required for the vancomycin-induced resistance response and are members of a two-component regulatory system directing the transcription of vanH, vanA, and vanX. These genes encode the three proteins which are necessary ford-Ala-d-Lac synthesis and are thus essential for glycopeptide resistance (1). VanA is the pivotal enzyme, producing the ester d-Ala-d-Lac instead of the usual d-Ala-d-Ala dipeptide for incorporation into peptidoglycan precursors (9). VanH is an α-keto acid reductase (d-lactate dehydrogenase [d-LDH]) that supplies VanA with substrate by converting pyruvate intod-lactate (9), while VanX is a highly specificd,d-dipeptidase which hydrolyzes thed-Ala-d-Ala generated by the endogenous cell wall biosynthetic pathway but does not recognized-Ala-d-Lac (34, 43). This elegant system is the means by which VRE can overcome current antibiotic regimens. A second variant of this mechanism and gene structure is encountered and distributed on plasmids (42), conjugative chromosomal elements (32), or transposons (e.g., Tn1547 [31]) with thed-Ala-d-Lac ligase designated VanB (18, 33).

The origin of the vanH, vanA/B, andvanX (vanHAX) resistance cassette has remained obscure. Both the intrinsically vancomycin-resistant lactic acid bacteria, such as organisms from the generaLeuconostoc, Pediococcus, andLactobacillus, and the glycopeptide-producing organisms are potential reservoirs. Alternatively, the genes may have arisen through mutations in homologous genes within enterococci or other organisms. The vancomycin-resistant lactic acid bacteria such as Leuconostoc mesenteroides have both the requisited-Ala-d-Lac ligase (15, 29) andd-LDH (12) enzymes, although thed-Ala-d-Lac ligases differ in their primary sequence from VanA/B, notably in the ω-loop region which is critical to catalysis (16). We have recently cloned a gene encoding a VanA/B homolog, designated DdlM, from the glycopeptide antibiotic-producing organism Streptomyces toyocaensisNRRL 15009 (23). The striking homology between VanA/B and DdlM (62% identity, >77% similarity) suggested that these enzymes evolved from a common ancestor. Similarly, we reported a segment of the ligase gene (ddlN) cloned from the vancomycin-producing organism Amycolatopsis orientalisC329.2 which also encoded a clear VanA/B homolog (23). Importantly, the ω-loop segment is conserved between VanA, VanB, DdlM, and DdlN. Thus, these results suggested that the VanA/B enzymes originated in glycopeptide-producing organisms but that the origins of the VanH and VanX accessory proteins were unknown. We now report on the cloning and sequencing of genes encoding VanH and VanX homologs from the same glycopeptide producers as well as the presence ofvanHAX gene clusters in several other glycopeptide-producing organisms. The strong homology of the gene products and the arrangement of the cloned genes indicate a common origin for the vancomycin resistance genes in VRE and antibiotic-producing organisms.

MATERIALS AND METHODS

Cloning of vanX from S. toyocaensis NRRL 15009.Cloning of a vanX gene from S. toyocaensis NRRL 15009 (vanXst) was achieved by the isolation of a specific gene probe by PCR amplification and degenerate deoxyoligonucleotide primers p1 and p2 designed to amplify an internal vanX fragment of approximately 360 bp (Table 1). PCR amplification reactions contained S. toyocaensis NRRL 15009 total DNA as template (500 ng), 1 U of Taq polymerase, each deoxynucleoside triphosphate (dNTP) at a concentration of 0.4 mM, 1 μM primers, and 2 mM MgCl2. The 360-bp product was cloned into the pGEM-T plasmid vector (Promega), and both strands were sequenced. To isolate a clone encompassing the entire vanXst gene, the probe fragment was randomly labeled with 32P by using the Klenow fragment (4). Labeling reactions contained 200 ng of template, 1 μl of each PCR primer, 1× Klenow buffer (10 mM Tris-Cl [pH 7.5], 5 mM MgCl2, 7.5 mM dithiothreitol), and 10 U of the Klenow fragment in a final volume of 55 μl. This probe was used to screen Southern hybridization blots of total S. toyocaensis NRRL 15009 DNA which had been digested to completion with several restriction enzymes in separate experiments. Hybridizing fragments (5.2 kb) of DNA from digestion with PstI were cloned into pBluescript II KS+ (Stratagene), transformed intoEscherichia coli DH5α, and confirmed to contain thevanXst gene by colony hybridization. A 5.2-kb fragment was found to contain the vanXst gene and was sequenced in its entirety.

View this table:
  • View inline
  • View popup
Table 1.

Sequences of PCR primers used in this study

The vanH gene was located immediately upstream of theddlM gene, whose sequence we have reported previously (23).

Cloning of van genes from A. orientalisC329.2.Cloning of the A. orientalis C329.2vanHAX cluster was achieved essentially as described for thevanX gene of S. toyocaensis NRRL 15009. Avan gene probe was generated from A. orientalisC329.2 genomic DNA by degenerate PCR with primers p2 and p3 complementary to conserved sequences in vanA andvanX (Table 1). Each amplification reaction mixture consisted of 500 ng of total DNA from A. orientalis C329.2, 1× Taq buffer, 5% dimethyl sulfoxide, 2 mM MgCl2, each dNTP at a concentration of 0.4 mM, 1 U ofTaq polymerase, and 1 μM primers. The 1.3-kb product was cloned into pGEM-T (Promega), and this clone was used as a template to generate a 32P-radiolabeled oligonucleotide probe with the Klenow fragment. This probe was used to screen Southern blots of restriction endonuclease-digested A. orientalis C329.2 genomic DNA to identify a 3.5-kb BamHI product containingvan genes. This fragment was cloned into pGEM-7Z and was isolated by standard methods.

DNA sequencing.The nucleotide sequence of the S. toyocaensis NRRL 15009 gene cluster was determined with a series of nested deletions constructed by ExoIII-S1 nuclease digestion and through the synthesis of specific oligonucleotide primers. The gene cluster for A. orientalis C329.2 was sequenced by primer walking. DNA cycle sequencing was performed by B. Allore on an Applied Biosystems automated DNA sequencer at the MOBIX central facility at McMaster University.

Analysis of gene clusters in glycopeptide producing organisms.Total DNA was isolated from glycopeptide-producing organisms, and 10 to 20 μg was separated on a 1% TAE (Tris-acetate-EDTA)–agarose gel after digestion to completion withBamHI. The DNA was blotted onto nitrocellulose by standard methods. A vanHAX cluster oligonucleotide probe radiolabeled with 32P was generated as described above by using the cloned 3.5-kb BamHI fragment from A. orientalisC329.2 as template and primers p3 and p4 (Table 1). This probe was hybridized to genomic DNA restriction products, and the blot was washed under stringent conditions prior to exposure.

PCR amplification of vanHAX from glycopeptide-producing organisms.The presence of thevanHAX cluster in glycopeptide producers was also assessed by amplification of the cluster by PCR. Degenerate oligonucleotide primers complementary to conserved regions in VanH (primer p5) and VanX (primer p2) were designed to amplify nearly the entire cluster (Table1). The PCR mixtures (100 μl) contained 500 ng of total DNA, 1 U ofTaq polymerase, 1× Taq buffer, 5% dimethyl sulfoxide, 4 mM MgCl2, each dNTP at a concentration of 0.4 mM, and 1 μM primers. Forty cycles of 94, 55, and 72°C (1, 1, and 2 min, respectively) were required to produce a visible band of approximately 2.6 kb. This product was isolated, applied to a 1% TAE agarose gel, and blotted onto nitrocellulose. A 32P-labeledvanHAX probe was generated from A. orientalisC329.2 total DNA and primers p3 and p4 (Table 1).

Analysis of sequence data.Contiguous sequences were constructed by using the MegAlign software from DNA Star (Madison, Wis.). Open reading frames (ORFs) were screened in all six frames by using the program FRAME (8) to identify probable streptomycete ORFs. Protein sequence alignments were performed by using CLUSTAL W software (39), version 1.7, with the Blosum matrix with a gap penalty of 10 and a gap extension of 0.05.

Nucleotide sequence accession numbers.The nucleotide sequences of vanHst and ddlM(accession no. U82965), vanXst (accession no.AF039028), and the gene cluster from A. orientalisC329.2 (accession no. AF060799) have been deposited in GenBank.

RESULTS AND DISCUSSION

Cloning of van genes from S. toyocaensisNRRL 15009 and A. orientalis C329.2. S. toyocaensis NRRL 15009 and A. orientalis C329.2 are gram-positive microbes which produce the “aglyco” glycopeptide antibiotic A47934, a structural homolog of teicoplanin (44), and vancomycin, respectively. We cloned and sequenced an expanse ofS. toyocaensis NRRL 15009 DNA spanning 2,650 bp and a 3,470-bp fragment of DNA from A. orientalis C329.2. Each of these contains three ORFs whose products bear striking homology to VanH, VanA (23), and VanX of VRE (Fig.1). These genes have been designatedvanHst, ddlM (23), andvanXst, respectively, in S. toyocaensis and vanHaov, ddlN, and vanHaov, respectively, in A. orientalis C329.2. (This rather ponderous terminology is necessitated by the fact that various A. orientalisstrains produce different glycopeptide antibiotics; thus, the subscriptao designates A. orientalis and the subscript v indicates that it is vancomycin producer.)

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Comparison of glycopeptide resistance gene clusters from VRE and glycopeptide antibiotic-producing organisms.

No genes encoding the homologs of the two-component regulatory elements (VanR and VanS) of VRE, thed,d-carboxypeptidase (VanY), or the vancomycin-resistant enterococcus-associated proteins of unknown function (VanW or VanZ) were found in the DNA flanking thevanHAX cluster in either organism, although we did not explicitly screen for these and they may be located elsewhere in the chromosome. The 5′ region immediately upstream ofvanHst contains an ORF which encodes a putatived-Ala-d-Ala-adding enzyme (MurF) homolog, which we have designated MurX (23), and part of a gene homologous to femA which is required for the synthesis of the penta-Gly bridge that joins the peptidoglycan peptide strands and is associated with high-level methicillin resistance in staphylococci (13).

A 1.6-kb ORF, designated ORF1, is located 195 bp downstream fromvanXst. This ORF has associated promoter −30 and −10 sequences and thus does not appear to be part of avanHst-ddM-vanXst polycistronic message. The ORF1 amino acid sequence shows a high degree of homology [P(N)10−170 to 10−42 by BLAST search] to other bacterial proteins of unknown function. Analysis against the PROSITE database did not reveal any distinguishing or revealing features. Further sequencing of 2 kb of DNA downstream of ORF1 did not reveal any genes encoding proteins which could obviously be ascribed to peptidoglycan or glycopeptide antibiotic biosynthesis.

No complete ORFs were detected in the regions flanking thevanHAX cluster from A. orientalis, although only approximately 800 bp of flanking DNA was sequenced.

Putative streptomycete −20 (CGGGC) and −10 (CACATA) promoter sequences (36) are located upstream ofvanHst. No additional promoter sequences were found upstream of ddlM or vanXst; thus, these three genes appear to be driven by a single promoter, as is the case with the sequences of VRE. Putative −20 (CGGGG) and −10 (CCCATA) promoter sequences were also identified in the A. orientalis C329.2 cluster. Additionally, a possible terminator sequence located between bases 3228 and 3273 was identified.

The vanHst gene terminates 10 bases within the predicted 5′ end of the ddlM gene, and similarly,vanHaov also terminates 10 bases withinddlN (Fig. 2). These observations directly parallel the arrangement ofvanHA and vanA in Tn1546, where the vanHA termination codon begins 5 bases into the vanA gene (3) and in the VanB gene cluster where the vanHB termination codon similarly begins 5 bases into the vanB gene (Fig. 2) (17).

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Overlap of vanH and vanA homolog genes.

Sequence analysis of vanH and vanX from glycopeptide producing organisms.The predicted amino acid sequence of VanHst and VanHaov clearly identify them as d-LDHs. Amino acid residues which are thought to participate in catalysis based on site-directed mutagenesis studies (21, 37, 38) of d-LDHs, as well as the three-dimensional structure of the Lactobacillus pentosusd-LDH (35), are conserved in VanHstand VanHaov. For example, a conserved Arg (Arg237 in VanHst and Arg255 in VanHaov) is predicted to bind to the carboxylate and polarize the ketone carbonyl for reduction, and an invariant His (His298 in VanHst and His316 in VanHaov) is predicted to act as an active-site general acid donating a proton during pyruvate reduction. Protein sequence alignment of VanHst and VanHaov with the VanH enzymes from VRE yielded overall amino acid identities of 51 to 55%, while alignment with other d-LDHs resulted in identities ranging from 26 to 31%. Phylogenetic analysis clearly places all the VanH enzymes in a distinct branch of the d-LDH family (Fig.3), an observation which parallels the clustering of DdlM and DdlN with VanA and VanB within thed-Ala-d-Ala ligase family (Fig.4) (23).

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Phylogenetic relationship among VanH homologs as calculated by the CLUSTAL W method (39). The tree was generated with the PHYLIP program Drawtree (19).Lact., Lactobacillus.

Fig. 4.
  • Open in new tab
  • Download powerpoint
Fig. 4.

Phylogenetic relationship amongd-Ala-d-Ala ligase homologs as calculated by the CLUSTAL W method (39). The tree was generated with the PHYLIP program Drawtree (19). The four major branches of the tree are labeled A, B, C, and D.

Phylogenetic analysis of the d-Ala-d-Ala ligases indicates four major groups (Fig. 4): the A and B groups, which are bona fide d-Ala-d-Ala ligases but which also contain the d-Ala-d-Lac ligases from lactic acid bacteria; the VanC group, which ared-Ala-d-Ser ligases and which confer constitutive low-level vancomycin resistance in several organisms such as Enterococcus gallinarum and Enterococcus casseliflavus (14, 28); and the VanA group, which consists of the d-Ala-d-Lac ligases from VRE and glycopeptide-producing organisms.

Amino acid sequence alignment of VanXst and VanXaov with the homologs from VRE confirms the presence of the Zn2+ binding ligands His116, Asp123, and His184 as well as the putative active site base Glu181 (25) (Fig.5). The VanXst and VanXaov proteins show 61 to 63% identity (>75% similarity) to the homologous proteins in VRE.

Fig. 5.
  • Open in new tab
  • Download powerpoint
Fig. 5.

Overlap of the Zn2+ binding regions of VanX proteins. The alignment was as calculated by the CLUSTAL W method (39). The Zn2+ ligands are boxed, and the putative active site base is indicated with an arrow.

Identification of vanHAX gene clusters in other glycopeptide antibiotic-producing organisms.Several other glycopeptide-producing organisms were screened for the presence of thevanHAX genes by two methods. First, a part of the gene cluster from A. orientalis C329.2 was amplified and used to probe total DNA that had been isolated from several glycopeptide producers and digested to completion withBamHI. A single hybridizing band was observed in producers of chloro-eremomycin, ristocetin, vancomycin, and teicoplanin-avoparcin (Fig. 6A), indicating that these organisms harbor similar genes. Second, a PCR screen was developed with degenerate primers complementary to conserved sequences in VanH and VanX. The presence of a vanHAX gene cluster should give rise to an amplified product of approximately 2.7 kb. By using total DNA from several glycopeptide-producing organisms, a band of the expected size was observed in all organisms tested, and the sequence represented by this band was confirmed to encode thevanHAX cluster by Southern hybridization with theA. orientalis C329.2 van cluster probe (Fig.6B). Thus, this gene cluster appears to be ubiquitously present in glycopeptide-producing bacteria.

Fig. 6.
  • Open in new tab
  • Download powerpoint
Fig. 6.

The presence of the vanHAX gene cluster in glycopeptide-producing organisms. (A) Southern blot of completeBamHI digests of A. orientalis 18098 (chloro-eremomycin producer) (lane 1), A. orientalissubsp. lurida (ristocetin producer) (lane 2), A. coloradensis subsp. labeda (teicoplanin and avoparcin producer) (lane 3), and A. orientalis C329.2 (vancomycin producer) (lane 4). The blot was probed with a portion of the ddlN gene amplified from A. orientalisC329.2. (B) Results of PCR amplification of the vanHAXcluster from glycopeptide-producing organism. The lane assignments and the blot probe are the same as described for panel A. Numbers to the left of the blots are in kilobases.

Implications of the van gene cluster in glycopeptide-producing organisms.In addition to the considerable similarity at the amino acid level noted above, the orientation and alignment of the vanHst, ddlM, andvanXst genes and thevanHaov, ddlN, andvanXaov genes in the glycopeptide producers is identical to the orientation of the homologous genes in VRE (Fig. 1). There are several implications of these findings. First, the fact that glycopeptide producers possess this gene cluster implies that they use a glycopeptide resistance mechanism which is similar to that found in VRE. Second, the presence of the vanXd,d-dipeptidase gene suggests that at some point during growth, the organisms switch from producing the conventional d-Ala-d-Ala peptidoglycan terminus to producing d-Ala-d-Lac. This is supported by our recent isolation of a dedicated d-Ala-d-Ala ligase which is incapable of d-Ala-d-Lac synthesis from S. toyocaensis NRRL 15009 cultures that are not producing the A47934 glycopeptide antibiotic (24).

More significant, however, are the evolutionary implications of these results. Phylogenetic analysis reveals that the gene products fromS. toyocaensis NRRL 15009, A. orientalis C329.2, and VRE form distinct subfamilies ofd-Ala-d-Ala ligases and d-LDHs. Furthermore, the spatial arrangements of the genes are maintained in both the antibiotic-producing and clinically resistant organisms, consistent with a common ancestry. Additionally, the signature overlap of the 5′ end of the vanA and homologous genes and the 3′ end of the vanH genes is conserved. Thus, the cumulative evidence indicates that the origin of clinically relevant vancomycin resistance lies within the glycopeptide-producing organisms and not the lactic acid bacteria, which also possess d-LDH andd-Ala-d-Lact ligase enzymes but whose enzymes are of a distinct lineage.

The G+C contents of the S. toyocaensis NRRL 15009 andA. orientalis C329.2 glycopeptide resistance genes are 65.3 and 63.6%, respectively, while the genes of VRE are less purine rich, with 44 and 49% purines for the VanA and VanB clusters, respectively. This weighs against recent direct transfer of the genes from either S. toyocaensis NRRL 15009 or A. orientalis C329.2 to enterococci, although other glycopeptide-producing organisms, with different G+C contents, may have served as donor. We note that the G+C contents of the VREvanH, vanA/B, and vanX elements are 5 to 10% higher than those of the adjacent vanR,vanS, vanY, and vanZ (orvanW) genes, consistent with mobilization of thevanH-vanA/B-vanX genes as a unit from another source into a context with appropriate control elements. It is also interesting that a difference in G+C content is also found in the flanking DNA of the gene clusters cloned from the glycopeptide-producing organisms, but here the flanking sequences show higher G+C contents: 69.9% forS. toyocaensis NRRL 15009 and 68.4% for A. orientalis C329.2. Thus, the resistance cluster may have been acquired by these organisms as well. On the basis of G+C content analysis and in the absence of more sequence information from other glycopeptide antibiotic-producing organisms, the source of the vanHAX cluster in VRE is not likely to be an actinomycete.

Alternatively, the resistance genes may have been acquired by non-glycopeptide-producing soil organisms as a method of defense, probably originally from a glycopeptide-producing organism, and then mobilized and passed on to other organisms, thus eventually diluting the original G+C content bias. It has been observed invanA-harboring Oerskovia (G+C content of 70 to 75 mol%) that two of the three nucleotide mutations present in its version of vanA serve to increase the G+C content (30). Whatever the mechanism of mobilization of thevanHAX cluster, if it originated in antibiotic-producing organisms, the transfer was not a recent event. However, the use of vast quantities of the glycopeptide antibiotic avoparcin over the past two decades in European agriculture may have provided the selective pressure for this mobilization or the enrichment of resistant organisms in the environment. The fact that enterococci harboring thevanA gene cluster on transposons such as Tn1546can be isolated from farm environments in Europe (5, 7) but not the United States (10, 26) is telling. Furthermore, the observation that VRE first emerged in Europe may therefore not be a coincidence, although another reservoir for VRE in the United States cannot be ruled out (26). For example, there has been a dramatic rise in the use of vancomycin in clinical settings since the early 1980s, especially in the United States (from 2,000 kg/year in 1984 to 11,200 kg/year in 1996 [20]), and this increase in antibiotic use must be considered when discussing the rise in the prevalence of VRE over the past decade. As an additional cautionary note, it has recently been demonstrated that many antibiotic formulations are contaminated with DNA from producing organisms (41); thus, a possible source for the dissemination of resistance genes exists, possibly as a contaminant in agricultural or clinical glycopeptide antibiotic formulations. The results described here should emphasize that caution must be employed in our use of antibiotics that, while not themselves clinically useful, have the potential to select for donors of resistance genes or preexisting resistant populations.

ACKNOWLEDGMENTS

This work was supported by an operating grant from the Natural Sciences and Engineering Research Council of Canada (NSERC), by a Medical Research Council of Canada Graduate (MRC) Studentship to C.G.M., by an NSERC Postdoctoral Fellowship to I.A.D.L., and by an MRC Scholar Award to G.D.W.

FOOTNOTES

    • Received 12 December 1997.
    • Returned for modification 10 February 1998.
    • Accepted 15 June 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Arthur M.,
    2. Molinas C.,
    3. Courvalin P.
    The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 174 1992 2582 2591
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Arthur M.,
    2. Molinas C.,
    3. Depardieu F.,
    4. Courvalin P.
    Characterization of Tn1546, a Tn3-related transposon conferring glycopeptide resistance by synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 175 1993 117 127
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Arthur M.,
    2. Molinas C.,
    3. Dutka-Malen S.,
    4. Courvalin P.
    Structural relationship between the vancomycin resistance protein VanH and 2-hydroxycarboxylic acid dehydrogenases. Gene 103 1991 133 134
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Ausubel F. M.,
    2. Brent R.,
    3. Kingston R. E.,
    4. Moore D. D.,
    5. Seidman J. G.,
    6. Smith J. A.,
    7. Struhl K.
    Current protocols in molecular biology. 1994 John Wiley & Sons, Inc. New York, N.Y
  5. 5.↵
    1. Bager F.,
    2. Madsen M.,
    3. Christensen J.,
    4. Aarestrup F. M.
    Avoparcin used as a growth promoter is associated with the occurrence of vancomycin-resistant Enterococcus faecium on Danish poultry and pig farms. Prev. Vet. Med. 31 1997 95 112
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Barna J. C. J.,
    2. Williams D. H.
    The structure and mode of action of glycopeptide antibiotics. Annu. Rev. Microbiol. 38 1984 339 357
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Bates J.,
    2. Jordens J. Z.,
    3. Griffiths D. T.
    Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J. Antimicrob. Chemother. 34 1994 507 516
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Bibb M. J.,
    2. Findlay P. R.,
    3. Johnson M. W.
    The relationship between base composition and codon usage in bacterial genes and its use for the simple and reliable identification of protein-coding sequences. Gene 30 1984 157 166
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Bugg T. D. H.,
    2. Wright G. D.,
    3. Dutka-Malen S.,
    4. Arthur M.,
    5. Courvalin P.,
    6. Walsh C. T.
    Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30 1991 10408 10415
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Coque T. M.,
    2. Tomayko J. F.,
    3. Ricke S. C.,
    4. Okhyusen P. C.,
    5. Murray B. E.
    Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob. Agents Chemother. 40 1996 2605 2609
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Cunha B. A.
    Vancomycin. Med. Clin. N. Am. 79 1995 817 831
    OpenUrlPubMedWeb of Science
  12. 12.↵
    1. Dartois V.,
    2. Phalip V.,
    3. Schmitt P.,
    4. Divies C.
    Purification, properties and DNA sequence of the d-lactate dehydrogenase from Leuconostoc mesenteroides subsp. cremoris. Res. Microbiol. 146 1995 291 302
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. de Lencastre H.,
    2. de Jonge B. L.,
    3. Matthews P. R.,
    4. Tomasz A.
    Molecular aspects of methicillin resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 33 1994 7 24
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Dutka-Malen S.,
    2. Molinas C.,
    3. Arthur M.,
    4. Courvalin P.
    Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a d-alanine:d-alanine ligase-related protein necessary for vancomycin resistance. Gene 112 1992 53 58
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Elisha B. G.,
    2. Courvalin P.
    Analysis of genes encoding d-alanine:d-alanine ligase-related enzymes in Leuconostoc mesenteroides and Lactobacillus spp. Gene 152 1995 79 83
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Evers S.,
    2. Casadewall B.,
    3. Charles M.,
    4. Dutka-Malen S.,
    5. Galimand M.,
    6. Courvalin P.
    Evolution of structure and substrate specificity in d-alanine:d-alanine ligases and related enzymes. J. Mol. Evol. 42 1996 706 712
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Evers S.,
    2. Courvalin P.
    Regulation of VanB-type vancomycin resistance gene expression by the VanSB-VanRB two-component regulatory system in Enterococcus faecalis V583. J. Bacteriol. 178 1996 1302 1309
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Evers S.,
    2. Sahm D. F.,
    3. Courvalin P.
    The vanB gene of vancomycin-resistant Enterococcus faecalis V583 is structurally related to genes encoding d-Ala:d-Ala ligases and glycopeptide-resistance proteins VanA and VanC. Gene 124 1993 143 144
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Felsenstein J.
    PHYLIP (Phylogeny Inference Package), version 3.5c. 1993Distributed by the author. Department of Genetics, University of Washington, Seattle.
  20. 20.↵
    1. Kirst H. A.,
    2. Thompson D. G.,
    3. Nicas T. I.
    Historical yearly usage of vancomycin. Antimicrob. Agents Chemother. 42 1998 1303 1304
    OpenUrlFREE Full Text
  21. 21.↵
    1. Kochhar S.,
    2. Chuard N.,
    3. Hottinger H.
    Glutamate 264 modulates the pH dependence of the NAD(+)-dependent d-lactate dehydrogenase. J. Biol. Chem. 267 1992 20298 20301
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Leclercq R.,
    2. Courvalin P.
    Resistance to glycopeptides in enterococci. Clin. Infect. Dis. 24 1997 545 554
    OpenUrlCrossRefPubMedWeb of Science
  23. 23.↵
    1. Marshall C. G.,
    2. Broadhead G.,
    3. Leskiw B.,
    4. Wright G. D.
    d-Ala-d-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc. Natl. Acad. Sci. USA 94 1997 6480 6483
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Marshall C. G.,
    2. Wright G. D.
    The glycopeptide antibiotic producer Streptomyces toyocaensis NRRL 15009 has both d-alanyl-d-alanine and d-alanyl-d-lactate ligases. FEMS Microbiol. Lett. 157 1997 295 299
    OpenUrlPubMedWeb of Science
  25. 25.↵
    1. McCafferty D. G.,
    2. Lessard I. A.,
    3. Walsh C. T.
    Mutational analysis of potential zinc-binding residues in the active site of the enterococcal d-Ala-d-Ala dipeptidase VanX. Biochemistry 36 1997 10498 10505
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. McDonald L. C.,
    2. Kuehnert M. J.,
    3. Tenover F. C.,
    4. Jarvis W. R.
    Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg. Infect. Dis. 3 1997 311 317
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Murray E.
    Vancomycin-resistant enterococci. Am. J. Med. 102 1997 284 293
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    1. Park I. S.,
    2. Lin C. H.,
    3. Walsh C. T.
    Bacterial resistance to vancomycin: overproduction, purification, and characterization of VanC2 from Enterococcus casseliflavus as a d-Ala-d-Ser ligase. Proc. Natl. Acad. Sci. USA 94 1997 10040 10044
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Park I. S.,
    2. Walsh C. T.
    d-Alanyl-d-lactate and d-alanyl-d-alanine synthesis by d-alanyl-d-alanine ligase from vancomycin-resistant Leuconostoc mesenteroides. Effects of a phenylalanine 261 to tyrosine mutation. J. Biol. Chem. 272 1997 9210 9214
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Power E. G. M.,
    2. Abdulla Y. H.,
    3. Talsania H. G.,
    4. Spice W.,
    5. Aathithan S.,
    6. French G. L.
    VanA genes in vancomycin-resistant clinical isolates of Oerskovia turbata and Arcanobacterium (Cornebacterium) haemolyticum. J. Antimicrob. Chemother. 36 1995 595 606
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    1. Quintiliani R. J.,
    2. Courvalin P.
    Characterization of Tn1547, a composite transposon flanked by the IS16 and IS256-like elements, that confers vancomycin resistance in Enterococcus faecalis BM428. Gene 172 1996 1 8
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Quintiliani R. J.,
    2. Courvalin P.
    Conjugal transfer of the vancomycin resistance determinant vanB between enterococci involves the movement of large genetic elements from chromosome to chromosome. FEMS Microbiol. Lett. 119 1994 359 363
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Quintiliani R. J.,
    2. Evers S.,
    3. Courvalin P.
    The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J. Infect. Dis. 167 1993 1220 1223
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Reynolds P. E.,
    2. Depardieu F.,
    3. Dutka-Malen S.,
    4. Arthur M.,
    5. Courvalin P.
    Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of d-alanyl-d-alanine. Mol. Microbiol. 13 1994 1065 1070
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Stoll V. S.,
    2. Kimber M. S.,
    3. Pai E. F.
    Insights into substrate binding by d-2-ketoacid dehydrogenases from the structure of Lactobacillus pentosusd-lactate dehydrogenase. Structure 4 1996 437 447
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Strohl W. R.
    Compilation and analysis of DNA sequences associated with apparent streptomycete promoters. Nucleic Acids Res. 20 1992 961 974
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Taguchi H.,
    2. Ohta T.
    Essential role of arginine 235 in the substrate-binding of Lactobacillus plantarumd-lactate dehydrogenase. J. Biochem. 115 1994 930 936
    OpenUrlPubMedWeb of Science
  38. 38.↵
    1. Taguchi H.,
    2. Ohta T.
    Histidine 296 is essential for the catalysis in Lactobacillus plantarumd-lactate dehydrogenase. J. Biol. Chem. 268 1993 18030 18034
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Thompson J. D.,
    2. Higgins D. G.,
    3. Gibson T. J.
    CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22 1994 4673 4680
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Walsh C. T.,
    2. Fisher S. L.,
    3. Park L.-S.,
    4. Prahalad M.,
    5. Wu Z.
    Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. 3 1996 21 28
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Webb V.,
    2. Davies J.
    Antibiotic preparations contain DNA: a source of drug resistance genes? Antimicrob. Agents Chemother. 37 1993 2379 2384
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Woodford N.,
    2. Jones B. L.,
    3. Baccus Z.,
    4. Ludlam H. A.,
    5. Brown D. F.
    Linkage of vancomycin and high-level gentamicin resistance genes on the same plasmid in a clinical isolate of Enterococcus faecalis. J. Antimicrob. Chemother. 35 1995 179 184
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Wu Z.,
    2. Wright G. D.,
    3. Walsh C. T.
    Overexpression, purification, and characterization of VanX, a d,d-dipeptidase which is essential for vancomycin resistance in Enterococcus faecium BM4147. Biochemistry 34 1995 2455 2463
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Zmijewski M. J. Jr.,
    2. Fayerman J. T.
    Glycopeptides Genetics and biochemistry of antibiotic production. Vining L. C., Stuttard C. 1994 269 281 Butterworth-Heinemann Boston, Mass
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Glycopeptide Antibiotic Resistance Genes in Glycopeptide-Producing Organisms
C. G. Marshall, I. A. D. Lessard, I.-S. Park, G. D. Wright
Antimicrobial Agents and Chemotherapy Sep 1998, 42 (9) 2215-2220; DOI: 10.1128/AAC.42.9.2215

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Glycopeptide Antibiotic Resistance Genes in Glycopeptide-Producing Organisms
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Glycopeptide Antibiotic Resistance Genes in Glycopeptide-Producing Organisms
C. G. Marshall, I. A. D. Lessard, I.-S. Park, G. D. Wright
Antimicrobial Agents and Chemotherapy Sep 1998, 42 (9) 2215-2220; DOI: 10.1128/AAC.42.9.2215
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS AND DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
Drug Resistance, Microbial
Genes, Bacterial
vancomycin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596